Dogwood Therapeutics IncDWTX
Price$1.43

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$36MTTM through 30 Jun 2026
Free Cash Flow -$15.1MTTM through 30 Jun 2026

Margins

Current

Returns

-6.2%ROE
-44.8%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.86x
Net Debt-$13.2Mnet cash position
Cash & Equivalents$9.6M

Quality Metrics

Altman Z-Score-1.09
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$1.89TTM
'20'21'22'23'24'25
FY2025: $-6.88

Dividend

No dividend

Capital Allocation

R&D Spend$22.8M

Segment Performance

SegmentRevenueYoYOutlook
Dogwood Therapeutics Single Segment$0
View details

Top-line results from the Halneuron Phase 2b CINP trial are expected in fall 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.